Rezolute Inc (RZLT)

$2.74 +0.32 (13.22%)
Market Cap 224.40M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,276,000
Avg Vol 6,666,626
Day's Range N/A - N/A
Shares Out 92.73M
Stochastic %K 94%
Beta 0.21
Analysts Strong Sell
Price Target $4.12

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
Monty3030
Monty3030 Dec. 25 at 3:49 PM
$RZLT Merry Christmas to the RZLT holders who stayed calm in chaos — and warm holiday wishes to those who panic sold and are now watching from the sidelines! 2026 will make a new high for RZLT!
0 · Reply
ShaunPetri911
ShaunPetri911 Dec. 25 at 3:31 PM
$RZLT biotech microcap under the radar volume ignition needed
0 · Reply
marti837
marti837 Dec. 25 at 2:42 PM
$RZLT For me, this story is over.
0 · Reply
WolfMoney
WolfMoney Dec. 25 at 2:08 PM
$RZLT time to load $SOC 👆🚨🚨🚨
0 · Reply
nokej13957
nokej13957 Dec. 25 at 8:10 AM
$RZLT
0 · Reply
RoyaltyStream
RoyaltyStream Dec. 25 at 8:09 AM
$RZLT Risk premia compress only when proof accumulates, with macro volatility magnifying operational missteps. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
Rumplenickledime
Rumplenickledime Dec. 25 at 1:26 AM
$RZLT $AMCI just amazing.🎉
0 · Reply
Nedwin513
Nedwin513 Dec. 24 at 9:23 PM
$RZLT Well accumulated. Trough holders (some loaded large) will realize 200% gains Friday as we cross into 3️⃣’s. Merry Christmas Happy Holidays and well done as we follow the money and avoid the noise.
1 · Reply
EvCe
EvCe Dec. 24 at 6:18 PM
$RZLT
0 · Reply
ofererez
ofererez Dec. 24 at 6:12 PM
$RZLT halt ?
1 · Reply
Latest News on RZLT
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Dec 23, 2025, 11:10 AM EST - 2 days ago

INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

Dec 23, 2025, 9:30 AM EST - 2 days ago

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Dec 19, 2025, 10:08 AM EST - 6 days ago

REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

RZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Dec 17, 2025, 4:31 PM EST - 7 days ago

RZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Dec 13, 2025, 7:38 AM EST - 12 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Dec 12, 2025, 3:00 PM EST - 12 days ago

RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

Dec 11, 2025, 7:59 PM EST - 13 days ago

Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Dec 11, 2025, 2:39 PM EST - 13 days ago

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript

Dec 11, 2025, 2:22 PM EST - 13 days ago

Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript

BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Dec 11, 2025, 10:39 AM EST - 14 days ago

BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Rezolute's rare disease drug fails main goal in late-stage trial

Dec 11, 2025, 7:05 AM EST - 14 days ago

Rezolute's rare disease drug fails main goal in late-stage trial

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Dec 11, 2025, 7:00 AM EST - 14 days ago

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move

Dec 8, 2025, 9:23 PM EST - 16 days ago

Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move

Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Nov 10, 2025, 7:51 PM EST - 6 weeks ago

Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 5:30 PM EST - 6 weeks ago

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 6 weeks ago

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Nov 5, 2025, 7:30 AM EST - 7 weeks ago

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Rezolute to Participate in Upcoming Investor Conferences

Oct 15, 2025, 8:00 AM EDT - 2 months ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 17, 2025, 4:05 PM EDT - 3 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Sep 16, 2025, 4:36 PM EDT - 3 months ago

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 12, 2025, 9:38 AM EDT - 3 months ago

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Sep 2, 2025, 7:30 AM EDT - 4 months ago

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Aug 20, 2025, 7:30 AM EDT - 4 months ago

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jul 22, 2025, 7:30 AM EDT - 5 months ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Jul 9, 2025, 7:30 AM EDT - 6 months ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025, 8:00 AM EDT - 7 months ago

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 8 months ago

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025, 8:00 AM EDT - 8 months ago

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025, 3:57 AM EDT - 8 months ago

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

Rezolute, Inc. Announces Closing of Underwritten Offering

Apr 25, 2025, 4:30 PM EDT - 8 months ago

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Apr 23, 2025, 3:50 PM EDT - 8 months ago

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Apr 23, 2025, 8:05 AM EDT - 8 months ago

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Apr 23, 2025, 8:00 AM EDT - 8 months ago

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Mar 26, 2025, 7:30 AM EDT - 9 months ago

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Feb 18, 2025, 1:30 AM EST - 11 months ago

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 11 months ago

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Feb 4, 2025, 8:00 AM EST - 11 months ago

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 11 months ago

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2024, 8:00 AM EST - 1 year ago

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Dec 3, 2024, 3:56 PM EST - 1 year ago

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 19, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

Sep 9, 2024, 10:41 AM EDT - 1 year ago

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

Sep 9, 2024, 7:47 AM EDT - 1 year ago

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Sep 9, 2024, 7:30 AM EDT - 1 year ago

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Monty3030
Monty3030 Dec. 25 at 3:49 PM
$RZLT Merry Christmas to the RZLT holders who stayed calm in chaos — and warm holiday wishes to those who panic sold and are now watching from the sidelines! 2026 will make a new high for RZLT!
0 · Reply
ShaunPetri911
ShaunPetri911 Dec. 25 at 3:31 PM
$RZLT biotech microcap under the radar volume ignition needed
0 · Reply
marti837
marti837 Dec. 25 at 2:42 PM
$RZLT For me, this story is over.
0 · Reply
WolfMoney
WolfMoney Dec. 25 at 2:08 PM
$RZLT time to load $SOC 👆🚨🚨🚨
0 · Reply
nokej13957
nokej13957 Dec. 25 at 8:10 AM
$RZLT
0 · Reply
RoyaltyStream
RoyaltyStream Dec. 25 at 8:09 AM
$RZLT Risk premia compress only when proof accumulates, with macro volatility magnifying operational missteps. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
Rumplenickledime
Rumplenickledime Dec. 25 at 1:26 AM
$RZLT $AMCI just amazing.🎉
0 · Reply
Nedwin513
Nedwin513 Dec. 24 at 9:23 PM
$RZLT Well accumulated. Trough holders (some loaded large) will realize 200% gains Friday as we cross into 3️⃣’s. Merry Christmas Happy Holidays and well done as we follow the money and avoid the noise.
1 · Reply
EvCe
EvCe Dec. 24 at 6:18 PM
$RZLT
0 · Reply
ofererez
ofererez Dec. 24 at 6:12 PM
$RZLT halt ?
1 · Reply
MaskedJoe
MaskedJoe Dec. 24 at 5:58 PM
$RZLT puts
0 · Reply
Skamiller
Skamiller Dec. 24 at 5:22 PM
$RZLT
0 · Reply
hihir81198
hihir81198 Dec. 24 at 5:14 PM
$RZLT
0 · Reply
Nedwin513
Nedwin513 Dec. 24 at 4:54 PM
$RZLT Strength
0 · Reply
J_Wayne
J_Wayne Dec. 24 at 4:41 PM
$RZLT was really excited about the share price today. January 16 2.50 calls that I bought for 6¢ were deep in the money. Was so tempted to hold Hold for the jackpot, but I took it off the table. GLTA.
1 · Reply
Klipse05
Klipse05 Dec. 24 at 4:39 PM
$RZLT what a wonderful Christmas gift. God bless.
0 · Reply
EvCe
EvCe Dec. 24 at 4:03 PM
$RZLT day traders are out and we’re moving all the way up! 🚀🎄🫡
0 · Reply
familymoney
familymoney Dec. 24 at 3:52 PM
$RZLT I predict we close above $2.85 What’s your thoughts. Are you holding?
0 · Reply
Jacklin123
Jacklin123 Dec. 24 at 3:32 PM
$RZLT still holding
0 · Reply
oaksapollo
oaksapollo Dec. 24 at 3:28 PM
$RZLT Based on their breakthrough status for ersodetug in cHI and the current stalled status of the program, Rezolute likely can get a type A meeting with FDA, which has to take place within 30 days of the request. Assuming they were able to put together a briefing book within 1 week of the top line data, they could be meeting with FDA as soon as Jan 16th, and that clarity on the cHI indication could easily double the stock from here. If no path forward in cHI, I don't think there is much downside from here, the market is already assuming tumor HI is the main indication. Good luck, happy holidays to all.
0 · Reply
UrusCapital
UrusCapital Dec. 24 at 3:10 PM
$OMER IS UP 100% ON THE DAY & CLIMBING AFTER HUGE FDA APPROVAL NEWS ON LIFE CHANGING STEM CELL DRUG!!!🔥🔥🔥💲 $RZLT $SOC $SNDL $DJT
0 · Reply
Benbobaggins
Benbobaggins Dec. 24 at 3:01 PM
$RZLT to any big ballers out there. You will have saved a life today 🙏🏼❤️
1 · Reply